The first data has emerged on the uptake of Novo Nordisk's new oral version of GLP-1 agonist weight-loss therapy Wegovy, with encouraging signs of strong demand as a potential rival from Eli Lilly waits for an FDA decision on approval.
There were 3,071 prescriptions for the Wegovy (semaglutide) pill in its first four days on the market after being approved by the FDA at the end of last year and launched on 5th January, according to IQVIA data shared by analysts and reported by Reuters. According to Barclays, that figure only covers retail pharmacy sales – not those through Novo Nordisk's own direct-to-consumer channel, NovoCare Pharmacy – so the total number should be higher. https://pharmaphorum.com/news/...hows-strong-early-uptake-rival-looms
Wegovy Pille zur Wegovy Spritze - Markteintritt Vergleich:
To put this "+4.000+" into perspective, let´s look at the history: Injectable Wegovy: Only 174 scripts in its 2an week(it took 3 weeks just to hit 1.000). Lilly´s Zepbound: Managed 1.911 in its 2an week. The Wegovy pill is outperforming the Zepbound launch by over 2x and its own injectable predecessor by a staggering 24x. And remember, these are retail-only numbers. They dont even include the massive wave of independent and direct-to-consumer telehealth volume. If retail is at 4k, the real total is likely north 10.000. NVO is reclaiming the throne. The "Pill Era" is here, the price war is won, and there is no stopping this train to 70 USD and beyond...https://seekingalpha.com/news/...-wins-3071-prescriptions-wegovy-pill
|
